Meet the team

Allison thrives on bringing clarity to complex situations, maximizing opportunities, and driving innovation within the Canadian specialty pharmaceutical industry to the benefit of patients.

Since 2019, Allison has co-chaired the RWE & Outcomes-Based Agreements Working Group, which has the mandate to advance outcomes-based agreements in Canada to benefit all stakeholders in the Canadian healthcare system.

As publisher of the Canadian quarterly magazine The 20Sense Report, she shares market insights that are pushing innovation and creating value for Canadian patients and the larger specialty pharmaceutical industry.

Allison routinely speaks and writes on the topic of specialty pharmaceuticals and outcome-based agreements in the Canadian context.

Arif supports the Canadian specialty pharmaceutical industry as a strategic project manager with expertise in research, analytics, and data.

Arif is an Industrial Engineer by trade. His passion for numbers, finding solutions for complex problems, and creating value for specialty pharmaceutical stakeholders is only second to his drive to find, implement, and optimize long-term innovation for Canadian patients.

With over 15 years in the specialty pharmaceutical industry, Arif applies his engineering skills to find solutions, build strategy, and optimize systems – enabling clients get their products to patients and track performance effectively. 

He supports clients by applying analytics, process design, and innovation techniques to find solutions to complex situations.

Arif has co-chaired the RWE & OBA Working Group since 2019. This working group is collaboratively developing and implementing OBA models that support timely and equitable patient access to novel therapies and value-based healthcare for all.